ArticleDiscover oncology2025
Hypoxia- and lactate metabolism-associated prognostic and therapeutic signature in pancreatic cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of solute carrier family 7 member 7 in cancer: opportunities for tumor microenvironment research.Journal for immunotherapy of cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypoxia and lactate metabolism products are critical components of the tumor microenvironment in pancreatic cancer (PC), influencing tumor invasiveness, metastasis, and treatment resistance. This study aims to explore the role of hypoxia- and lactate metabolism-related genes (HLRGs) in predicting overall survival and guiding treatment for PC patients.
methodsGene expression and clinical data from PC patients were obtained from TCGA, ICGC, and GEO. Normal pancreatic tissue data were sourced from GTEx. Differential expression analysis was performed on the merged TCGA-PAAD and GTEx cohorts to identify differentially expressed genes (DEGs). We performed an intersection analysis between the DEGs and the HLRGs obtained from the MsigDB database to identify the DEGs associated with hypoxia and lactate metabolism in PC. A prognostic model was developed using random survival forests, Cox regression, and LASSO analysis in the TCGA-PAAD cohort. The model was externally validated in the ICGC-PACA and GSE85916 cohorts. Risk stratification was performed, and the differences between subgroups in tumor mutational burden, immune microenvironment, and drug response were analyzed. RT-qPCR validated the key genes expression differences.
resultsA prognostic model based on HLRGs (SLC7A7, PYGL, HS3ST1, DDIT4, CYP27A1, ANKZF1, COL5A1) was established. High-risk patients exhibited worse prognosis, higher tumor mutational burden, and better response to anti-PD-L1 therapy, while low-risk patients exhibited higher immune infiltration and increased chemotherapy sensitivity. RT-qPCR confirmed that SLC7A7 and COL5A1 were upregulated, while ANKZF1 was downregulated in PC.
conclusionsWe developed an HLRGs-based prognostic model that predicts overall survival and guides treatment strategies, contributing to precision therapy in PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.